Patient-reported adverse events in PROSPECT, a randomized trial of chemotherapy with selective use of pelvic chemoradiation to standard use of chemoradiation for neoadjuvant treatment of locally advanced rectal cancer (Alliance N1048)
   Google Scholar   
Citation:
J Clin Oncol vol 41 (supp 17) LBA2
Meeting Instance:
ASCO 2023
Year:
2023
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
4019  
Program:
CCP
Primary Committee:
Health Outcomes
Sec. Committees:
GI    
Pharmas:
 
Grants:
UG1CA189823, U10CA180821, U10CA180882; U10CA180863, Canadian Cancer Society Grant # 707213 (CCTG); U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG); U01CA233046, HHSN261200800063C  
Corr. Author:
 
Authors:
                                           
Networks:
LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, PA086, SCOR   
Study
NCCTG-N1048
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2/3
Keywords: